Transgene (TNG.PA) Stock Price
Transgene Price
Revenue has compounded at 2.0% per year over the past 19 years to 6.08 M EUR. Transgene's net margin stands at -558.6%, down from -184.4% several years earlier. Analysts set a median price target of 1.38 EUR, implying 81.2% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 8% above its 52-week low.
Transgene stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Transgene over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Transgene stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Transgene's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Transgene Price |
|---|---|
| 9/25/2026 | 0.76 EUR |
| 9/24/2026 | 0.81 EUR |
| 9/23/2026 | 0.85 EUR |
| 9/22/2026 | 0.85 EUR |
| 9/21/2026 | 0.85 EUR |
| 9/18/2026 | 0.86 EUR |
| 9/17/2026 | 0.86 EUR |
| 9/16/2026 | 0.86 EUR |
| 9/15/2026 | 0.87 EUR |
| 9/14/2026 | 0.88 EUR |
| 9/11/2026 | 0.88 EUR |
| 9/10/2026 | 0.88 EUR |
| 9/9/2026 | 0.88 EUR |
| 9/8/2026 | 0.88 EUR |
| 9/7/2026 | 0.90 EUR |
| 9/4/2026 | 0.86 EUR |
| 9/3/2026 | 0.88 EUR |
| 9/2/2026 | 0.79 EUR |
| 9/1/2026 | 0.79 EUR |
| 8/31/2026 | 0.80 EUR |
| 8/28/2026 | 0.80 EUR |
| 8/27/2026 | 0.81 EUR |
| 8/26/2026 | 0.81 EUR |
| 8/25/2026 | 0.81 EUR |
| 8/21/2026 | 0.81 EUR |
| 8/20/2026 | 0.84 EUR |
| 8/19/2026 | 0.73 EUR |
| 8/18/2026 | 0.73 EUR |
| 8/17/2026 | 0.73 EUR |
| 8/14/2026 | 0.72 EUR |
Transgene Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Transgene Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.00 | 8.00 | 7.00 | 7.00 | 13.00 | 9.00 | 17.00 | 10.00 | 7.00 | 6.00 | 6.00 | 7.00 | 7.00 | 42.00 | 18.00 | 12.00 |
| -18.18 | -11.11 | -12.50 | – | 85.71 | -30.77 | 88.89 | -41.18 | -30.00 | -14.29 | – | 16.67 | – | 500.00 | -57.14 | -33.33 |
| -233.33 | -262.50 | -300.00 | -300.00 | -161.54 | -188.89 | -88.24 | -210.00 | -300.00 | -350.00 | -210.00 | -210.00 | -210.00 | -210.00 | -210.00 | -210.00 |
| -21.00 | -21.00 | -21.00 | -21.00 | -21.00 | -17.00 | -15.00 | -21.00 | -21.00 | -21.00 | -12.60 | -14.70 | -14.70 | -88.20 | -37.80 | -25.20 |
| -28.00 | -22.00 | -27.00 | 7.00 | -25.00 | -23.00 | -23.00 | -29.00 | -30.00 | -35.00 | -15.00 | -17.00 | -23.00 | -10.00 | -20.00 | -27.00 |
| -311.11 | -275.00 | -385.71 | 100.00 | -192.31 | -255.56 | -135.29 | -290.00 | -428.57 | -583.33 | -250.00 | -242.86 | -328.57 | -23.81 | -111.11 | -225.00 |
| -46.00 | -25.00 | -32.00 | 8.00 | -18.00 | -17.00 | -19.00 | -32.00 | -22.00 | -33.00 | -12.00 | -16.00 | -25.00 | -9.00 | -17.00 | -23.00 |
| -4.17 | -45.65 | 28.00 | -125.00 | -325.00 | -5.56 | 11.76 | 68.42 | -31.25 | 50.00 | -63.64 | 33.33 | 56.25 | -64.00 | 88.89 | 35.29 |
| 40.38 | 57.45 | 63.67 | 63.87 | 81.76 | 83.84 | 91.11 | 99.50 | 100.59 | 116.67 | 116.67 | 116.67 | 116.67 | 116.67 | 116.67 | 116.67 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Transgene generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Transgene retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Transgene's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Transgene has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Transgene's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Transgene stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Transgene Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Transgene business model & stock analysis
Transgene SWOT Analysis
Strengths
Transgene SA possesses several strengths that contribute to its success in the market:
- Strong research and development capabilities, allowing for continual innovation in biotechnology.
- Wide range of intellectual property rights and patents, providing a competitive advantage and protecting their innovations.
- Strong financial position with access to funding, enabling the company to invest in research and development.
- Established partnerships and collaborations with reputable organizations, enhancing their research capabilities and market reach.
Weaknesses
Despite its strengths, Transgene SA also faces certain weaknesses that could hinder its growth:
- Dependency on a limited number of key partners, making the company vulnerable to changes in these partnerships.
- Relatively small market presence compared to larger biotech companies, limiting their ability to compete on a global scale.
- High research and development costs, potentially impacting their profitability in the short term.
- Limited product portfolio, which may restrict their market opportunities and ability to generate revenue.
Opportunities
Transgene SA can leverage the following opportunities to grow and expand its business:
- Increasing demand for innovative biotechnology solutions in the healthcare industry.
- Emerging markets with untapped potential, providing growth opportunities.
- Advancements in technology and genomic research, opening up new possibilities for product development.
- Collaborations with academic and research institutions to enhance their scientific capabilities.
Threats
Transgene SA faces certain threats that could affect its future performance and market position:
- Competitive landscape with the presence of well-established biotech companies, posing a challenge in market penetration.
- Stringent regulatory requirements and approval processes for new biotechnological products.
- Technological advancements by competitors, potentially rendering Transgene's current products less competitive.
- Economic fluctuations and uncertainties, which may impact the company's financial stability and funding opportunities.
Transgene Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Transgene historical P/E ratio, EBIT multiple, and P/S ratio
Transgene annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Transgene's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Transgene's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Transgene's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Transgene shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Transgene stock splits
Since 2000, a total of 1 shares have been converted from one Transgene share.
Current Transgene forecasts and price targets in September 2026
Analyst Price Targets 2026Transgene Earnings Calls
Transgene Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 9/24/2026 | -EUR | -0.06EUR | 36,637.00EUR | - | 2026 Q3 |
| 9/16/2025 | -EUR | -0.15EUR | 102,096.00EUR | - | 2025 Q3 |
| 4/24/2025 | -EUR | -0.13EUR | 96,000.00EUR | - | 2025 Q1 |
| 3/27/2024 | -0.21EUR | -0.16EUR | 6.70 MEUR | - | 2024 Q1 |
| 5/10/2023 | -0.24EUR | -0.18EUR | 3.80 MEUR | - | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Transgene stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Transgene Beneficial Ownership Filings (SEC 13D/G)
Transgene Executives and Management Board
18 members · avg. age 56 · 50 % women
Dr. Alessandro Riva (64)
Chairman of the Board, Chief Executive Officer, Member of the Management Committee · since 2022
740,000.00 EUR
Management
Mr. Christophe Ancel (61)
Chief Quality Officer and Qualified Pharmacist, Director of Pharmaceutical Operations and Chief Pharmacist - Deputy Chief Executive Officer, Member of the Management Committee
Ms. Lucie Larguier (41)
Chief Financial Officer, Member of the Management Committee
Ms. Christelle Schwoerer (33)
Chief Human Resources Officer, Member of the Management Committee
Ms. Simone Steiner (49)
Chief Technology Officer, Member of the Management Committee
Dr. Maurizio Ceppi (53)
Chief Scientific Officer, Member of the Management Committee
Mr. John Felitti (55)
General Counsel, Corporate Secretary, Member of the Management Committee
Board of Directors
Dr. Maya Said (48)
Non-Executive Independent Director
Ms. Carol Stuckley (69)
Non-Executive Independent Director
Ms. Marie-Yvonne Landel (72)
Non-Executive Independent Director
Mr. Benoit Habert (60)
Non-Executive Director
Prof. Jean-Yves Blay (64)
Non-Executive Independent Director
Mr. Jean-Luc Belingard (76)
Non-Executive Director
Frequently asked questions about Transgene
The business model of Transgene SA is focused on developing innovative immunotherapies for the treatment of cancer and infectious diseases. As a biotechnology company, Transgene SA utilizes its expertise in viral vector technology to design and manufacture targeted therapies. The company conducts extensive research and clinical trials to validate the efficacy and safety of its treatments. Transgene SA also collaborates with strategic partners and pharmaceutical companies to enhance the development and commercialization of its products. By leveraging its innovative approach and strategic alliances, Transgene SA aims to address unmet medical needs and improve patient outcomes in the field of immunotherapy.
Transgene SA is primarily active in the biotechnology industry. As a leading company in the field, Transgene focuses on developing innovative immunotherapies for treating different types of cancer. By leveraging its expertise in viral vector technology, Transgene aims to provide breakthrough solutions that can enhance the immune system's ability to fight cancer cells effectively. With its strong commitment to research and development, Transgene strives to bring novel therapies to patients, contributing to the advancement of cancer treatment options.
The main competitors of Transgene SA in the market are other biotechnology companies that operate within the same sector, such as BioNTech SE, Cellectis SA, and CRISPR Therapeutics AG. These companies also focus on developing innovative therapies and treatments to address various diseases and medical conditions. However, Transgene SA distinguishes itself by leveraging its proprietary technologies, such as its gene therapy platform and viral vector system, to advance its pipeline of potential treatments. By continuously exploring cutting-edge research and collaborations, Transgene SA aims to establish a strong presence and competitive edge in the biotechnology market.
Transgene SA is a leading biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. Established in 1979, Transgene has a rich history of innovation and scientific expertise. The company has dedicated its efforts to leveraging the power of viruses to deliver therapeutic agents directly into cells, enabling targeted and potent treatments. Transgene has collaborated with renowned partners and successfully advanced multiple programs into clinical trials. With a strong commitment to improving patient outcomes, Transgene SA continues to pave the way in the field of immunotherapy, offering promising prospects for the future of cancer treatments.
Transgene SA, a leading biotechnology company, has achieved significant milestones throughout its history. The company has successfully developed and advanced innovative immunotherapies, focusing on viral vector-based platforms. It has conducted rigorous clinical trials and received regulatory approvals for its potential breakthrough treatments. Transgene SA has forged strategic partnerships with renowned pharmaceutical companies, facilitating the advancement of its product portfolio. The company has also demonstrated its expertise in translational research, presenting promising results and publications in reputable scientific journals. These milestones highlight Transgene SA's commitment to revolutionizing the treatment landscape for various diseases, solidifying its reputation as a key player in the biotech industry.
Transgene SA is primarily present in France, with its headquarters located in Strasbourg. It is a biotechnology company that focuses on designing and developing immunotherapy products to target and treat cancer and infectious diseases. With a strong presence in France, Transgene SA operates globally, collaborating with international research centers, universities, and pharmaceutical companies to advance its innovative treatments. The company's dedication to revolutionizing healthcare extends beyond borders, as it continues to expand its presence and partnerships to bring its cutting-edge therapies to patients worldwide.
Transgene SA is a leading biotechnology company dedicated to revolutionizing the field of immunotherapy. With a strong focus on patient care, Transgene aims to develop innovative treatments for various types of cancer and infectious diseases. The company's core values encompass excellence, integrity, and collaboration, as it strives to deliver breakthrough therapies that significantly impact patients' lives. Transgene's corporate philosophy emphasizes the importance of scientific innovation, while maintaining the highest ethical standards. Through cutting-edge research and strategic partnerships, Transgene SA is committed to advancing the next generation of immunotherapies and bringing hope to patients worldwide.
Analysts currently set an average price target of 1.38 EUR for the Transgene stock (median: 1.38 EUR), implying +81.2 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Transgene stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Transgene to generate revenue of 7.20 M EUR and earnings per share of -0.14 EUR.
The Transgene share (TNG.PA) is listed on 7 stock exchanges, including: London (0OCQ.L), Frankfurt (TGNA.F), München (TGNA.MU), Paris (TNG.PA).
Transgene SA is a French company specialized in the development and manufacturing of immunoncological therapies. The company's business model focuses on identifying new target molecules that can be used in cancer therapy and developing therapeutics based on this. Transgene conducts research and development mainly in the area of adeno-associated viruses (AAV) and gene editing. The company is organized into four main business areas. The first one is cancer immunotherapy, where Transgene focuses on developing treatment options for solid tumors. This includes research on new strategies to enhance the effectiveness of immunotherapies and overcome resistance. Another business area of Transgene is new therapeutic approaches, where the company works on innovative compounds based on AAV technology. The potential of the AAV platform is used to develop new treatment options for various diseases. Transgene is also active in the gene editing business area. The focus here is on developing effective methods for genome editing technology to treat and potentially cure genetic diseases. Another important area for Transgene is the licensing of technologies and products. The company has already completed several successful partnerships and is developing joint products with various partners. For example, the company cooperates with AstraZeneca in the development of immunotherapies against solid tumors. One of Transgene's most important products is the oncolytic virus TG6002. This vaccine is based on AAV technology and is designed for the treatment of solid tumors. The virus serves as a carrier for delivering tumor cell-destroying agents into the tumor cells. Apoptosis, or programmed cell death, is used to kill the tumor cells. Another important product for Transgene is the drug NG-348. This is an antibody drug conjugate (ADC) developed for the treatment of various types of cancer. It combines an antibody with a drug against tumor cells. Overall, Transgene follows a business model strongly focused on research and development. The company invests significant amounts in research and development to develop innovative solutions for the treatment of cancer and other diseases. Collaboration with other companies is intended to accelerate the market readiness of the products. Transgene aims to strengthen its position as a leading developer of immunoncological therapies and increase the global availability of its products.
The expected revenue of Transgene is 7.20 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Transgene is -16.33 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Transgene is currently -5.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Transgene stock.
The price-to-sales ratio (P/S) of Transgene is currently 12.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Transgene stock.
The Eulerpool Quality Score for Transgene is 1/10.
The ISIN of Transgene is FR0005175080. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Transgene is 913048. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Transgene is TNG.PA. The ticker symbol is used to trade Transgene shares on the stock exchange.
Transgene paid dividends every year for the past 0 years.
Transgene is assigned to the 'Health' sector.
The dividends of Transgene are distributed in EUR.
Transgene stock
Transgene Peer Group
Transgene Ticker
Transgene FIGI
All fundamentals and in-depth analysis of Transgene
Our stock analysis for Transgene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Transgene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.